Oxaliplatin

別名：L-OHP,NSC 266046

製品コード：S1224 純度：99.78%

Oxaliplatin is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.Solutions are unstable and should be fresh-prepared.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.

CAS No. 61825-94-3

サイズ	価格(税別)	在庫状況
50mg	JPY 22000	国内在庫あり
200mg	JPY 41500	国内在庫あり
1g	JPY 145500	国内在庫なし(納期7~10日)
10g	JPY 595500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（222）

製品安全説明書

現在のバッチを見る：純度： 99.78%

99.78

Oxaliplatin関連製品

関連ターゲット	tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase	もっと見る
関連製品	Cisplatin Gemcitabine 5-FU (5-Fluorouracil) TMZ(Temozolomide) Gemcitabine HCl Cytarabine Pidnarulex (CX-5461) Fludarabine Phosphate Hydroxyurea Sofosbuvir SCR7 Bendamustine HCl Capecitabine Cytarabine hydrochloride Favipiravir (T-705) m6A (N6-methyladenosine) Clofarabine RK-33 Lomustine Carmofur Ifosfamide Triapine (3-AP) Mercaptopurine (6-MP) B02 BMH-21 YK-4-279 Nelarabine Floxuridine (FUDR) BrdU (Bromodeoxyuridine) Procarbazine HCl Bergapten Chloroambucil Tegafur (FT-207) Cidofovir Azaguanine-8 Halofuginone Adenine HCl Fidaxomicin Mupirocin Mizoribine Cyclocytidine HCl Thymidine Cyclophosphamide Uridine APX-3330 Vidarabine Rifapentine Nedaplatin 6-Thio-dG Flupirtine maleate Carmustine JH-RE-06 Pritelivir (BAY 57-1293) TK216 Amenamevir Madrasin Tubercidin Rimantadine Hydrochloride BC-LI-0186 CRT0044876 PFM01 Adenine ML216 Rifaximin	もっと見る
関連化合物ライブラリー	FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	もっと見る

シグナル伝達経路

DNA/RNA Synthesisシグナル伝達経路

DNA/RNA Synthesis阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
SW620	Function Assay	10 µg/ml	24 h	increases LC3-II accumulation and decreases P62 expression	25749420
SW480	Function Assay	10 µg/ml	24 h	increases LC3-II accumulation and decreases P62 expression	25749420
SW620	Function Assay	10 µg/ml	24 h	enhances cellular autophagic flux	25749420
SW480	Function Assay	10 µg/ml	24 h	enhances cellular autophagic flux	25749420
Panc-1	Cell Viability Assay	25/50 μM	24/48 h	inhibits proliferation of PC cells in a synergistic manner combined with WA	25444914
MIAPaCa-2	Cell Viability Assay	25/50 μM	24/48 h	inhibits proliferation of PC cells in a synergistic manner combined with WA	25444914
SW1990	Cell Viability Assay	25/50 μM	24/48 h	inhibits proliferation of PC cells in a synergistic manner combined with WA	25444914
HPDE	Cell Viability Assay	25/50 μM	24/48 h	inhibits proliferation of PC cells in a synergistic manner combined with WA	25444914
Panc-1	Apoptosis Assay	25 µM	24 h	induces apoptosis in a synergistic manner combined with WA	25444914
MIAPaCa-2	Apoptosis Assay	25 µM	24 h	induces apoptosis in a synergistic manner combined with WA	25444914
Panc-1	Function Assay	25 µM	24/48 h	induces cleavage of PARP, caspase-9, caspase-8 and caspase-3	25444914
MIAPaCa-2	Function Assay	25 µM	24/48 h	induces cleavage of PARP, caspase-9, caspase-8 and caspase-3	25444914
SW480	Growth Inhibition Assay	1 μM	0-72 h	inhibits cell growth in a time dependent manner	24997451
HT-29	Growth Inhibition Assay	1 μM	0-72 h	inhibits cell growth in a time dependent manner	24997451
HCT116	Function Assay	2/5 µM	24/48 h	suppresses survivin mRNA expression	24761411
SW620	Growth Inhibition Assay	10-70 mg/L	24/48/72 h	inhibits cell growth in both time and dose dependent manner	24646305
Caco2	Function Assay	30 μM	24 h	induces the expression of HO-1, AKR1C, and NQO1	24556415
Caco2	Function Assay	3/10/30 μM	16 h	increases the mRNA levels of AKR1C1, NQO1, HO-1, MRP2, andMRP3 dose-dependently	24556415
Caco2	Function Assay	30/100 μM	16 h	activates Nrf2	24556415
CT26	Cell Viability Assay	4 mM	48 h	decreases cell viability to 53.2%	26137012
CT26	Function Assay	4 mM	48 h	increases the expression levels of autophagy-related proteins, such as LC3-II, Beclin1 and ATG5	26137012
CT26	Function Assay	4 mM	48 h	induces autophagy	26137012
SK-OV-3	Function Assay	50 μM	48 h	promotes sensitivity of ovarian carcinoma to NK cell-mediated cytolysis	26138671
OVCAR-5	Function Assay	20 μM	24h	promotes sensitivity of ovarian carcinoma to NK cell-mediated cytolysis	26138671
PA-1	Function Assay	10 μM	24h	promotes sensitivity of ovarian carcinoma to NK cell-mediated cytolysis	26138671
SK-OV-3	Function Assay	50 μM	96 h	up-regulates the stress ligands for NK cell-activating receptors and TRAIL receptors	26138671
OVCAR-5	Function Assay	30 μM	48h	up-regulates the stress ligands for NK cell-activating receptors and TRAIL receptors	26138671
PA-1	Function Assay	10 μM	48h	up-regulates the stress ligands for NK cell-activating receptors and TRAIL receptors	26138671
SK-OV-3	Function Assay	50 μM	96 h	triggeres the production of type I IFNs and chemokines	26138671
OVCAR-5	Function Assay	30 μM	48h	triggeres the production of type I IFNs and chemokines	26138671
PA-1	Function Assay	10 μM	24h	triggeres the production of type I IFNs and chemokines	26138671
SK-OV-3	Cell Viability Assay	0-100 μM	24/48/72 h	inhibits cell viability in both time and dose dependent manner	26138671
OVCAR-5	Cell Viability Assay	0-60 μM	24/48/72 h	inhibits cell viability in both time and dose dependent manner	26138671
PA-1	Cell Viability Assay	0-20 μM	24/48 h	inhibits cell viability in both time and dose dependent manner	26138671
LoVo	Function Assay	1/5 μM	24/48 h	induces transcriptional repression of DUT-N	26208523
HCT116 p53+/+	Function Assay	1/5 μM	24/48 h	induces transcriptional repression of DUT-N	26208523
CaES-17	Cytotoxicity Assay	0–160 μM	48 h	IC50=5.5 ± 0.2 μM	26474693
HKESC-2	Cytotoxicity Assay	0–160 μM	48 h	IC50=5.8 ± 0.5 μM	26474693
SW480	Growth Inhibition Assay		72 h	IC50=10.7±2.26 µg/mL	25360631
HCT116	Growth Inhibition Assay		72 h	IC50=6.23±0.75 µg/mL	25360631
SW480	Growth Inhibition Assay		48 h	IC50=20.8 ug/mL	24720675
LoVo	Growth Inhibition Assay		48 h	IC50=94.83 μM	26269759
HCT116	Growth Inhibition Assay		48 h	IC50=11.86 μM	26269759
SW480	Growth Inhibition Assay		48 h	IC50=1.87 μM	26269759
HT29	Growth Inhibition Assay			IC50=63 μM ± 18	26004084
DLD-1	Growth Inhibition Assay			IC50=32.2 μM	26003085
HT-29	Growth Inhibition Assay			IC50=35.6 μM	26003085
SiHa	Growth Inhibition Assay			IC50=0.8 ± 0.1 μM	25801007
S3	Growth Inhibition Assay			IC50=53.5 ± 1.5 μM	25801007
AGS	Growth Inhibition Assay			IC50=10.6 μM	25789057
MKN-45	Growth Inhibition Assay			IC50=14.0 μM	25789057
TMK-1	Growth Inhibition Assay			IC50=22.6 μM	25789057
SCM-1	Growth Inhibition Assay			IC50=17.5 μM	25789057
HCT-15	Growth Inhibition Assay			IC50=8.64 μM	25761479
DiFi	Growth Inhibition Assay			IC50=10.95 μM	25761479
DLD-1	Growth Inhibition Assay			IC50=8.65 μM	25761479
COLO-320DM	Growth Inhibition Assay			IC50=5.38 μM	25761479
SNU-175	Growth Inhibition Assay			IC50=1.51 μM	25761479
HT-29	Growth Inhibition Assay			IC50=5.22 μM	25761479
A549	Growth Inhibition Assay			IC50=5.8 ± 0.6 μM	25625243
A549/CDDP	Growth Inhibition Assay			IC50=18.6 ± 1.2 μM	25625243
COC1	Growth Inhibition Assay			IC50=46.20 ± 3.14 μM	25307448
SGC7901	Growth Inhibition Assay			IC50=21.73 ± 3.08 μM	25307448
A549	Growth Inhibition Assay			IC50=51.08 ± 10.96 μM	25307448
HepG2	Growth Inhibition Assay			IC50=14.24 ± 1.82 μM	25307448
MCF-7	Growth Inhibition Assay			IC50=14.24 ± 1.82 μM	25307448
HCT-116	Growth Inhibition Assay			IC50=6.24 ± 2.97 μM	25307448
HT-29	Growth Inhibition Assay			IC50>50 μM	25307448
HEK293	Growth Inhibition Assay			IC50=8.82 ± 5.59 μM	25307448
HUVEC	Growth Inhibition Assay			IC50=11.30 ± 1.02 μM	25307448
MC38	Growth Inhibition Assay			IC50=23 μM ± 2	26004084
SW620	Growth Inhibition Assay			IC50=3.68 μM	26023085
SW480	Growth Inhibition Assay			IC50=2.86 μM	26023085
RKO	Growth Inhibition Assay			IC50=1.23 μM	26023085
LoVo	Growth Inhibition Assay			IC50=1.2 μM	26023085
KM12	Growth Inhibition Assay			IC50=4.37 μM	26023085
HCT116p53-	Growth Inhibition Assay			IC50=1.08 μM	26023085
HCT116	Growth Inhibition Assay			IC50=1.04 μM	26023085
HCT15	Growth Inhibition Assay			IC50=1.43 μM	26023085
HT29	Growth Inhibition Assay			IC50=2.69 μM	26023085
DLD1	Growth Inhibition Assay			IC50=2.01 μM	26023085
Colo205	Growth Inhibition Assay			IC50=3.33 μM	26023085
BE	Growth Inhibition Assay			IC50=3.33 μM	26023085
HCT116	Growth Inhibition Assay			IC50=0.41 ± 0.02 μM	26148596
HT29	Growth Inhibition Assay			IC50=0.88 ± 0.2 μM	26148596
SNU-387	Growth Inhibition Assay			IC50=25 ± 2.7 μM	26160429
SNU-475	Growth Inhibition Assay			IC50＞30 μM	26160429
Hep-G2	Growth Inhibition Assay			IC50=13.1 ± 1.6 μM	26160429
SNU-398	Growth Inhibition Assay			IC50=6.5 ± 1.1 μM	26160429
MDA-MB-231	Growth Inhibition Assay			IC50=23.1 ± 0.1 μM	26211591
MCF-7	Growth Inhibition Assay			IC50=15.4 ± 0.3 μM	26211591
SK-BR-3	Growth Inhibition Assay			IC50=31.0 ± 0.1 μM	26211591
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

特性

This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[9]

Targets

DNA synthesis ^[1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)

In Vitro
In vitro	The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. ^[1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. ^[2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. ^[4]
細胞実験	細胞株	RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
	濃度	~100 μM
	反応時間	48 hours
	実験の流れ	The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO₂ and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 10³ cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	p-Src(Y418) / p-FAK(Y861) p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416) VEGFR-1 / NRP-1		19383922
	Immunofluorescence	ATXN2L / G3BP1 E-cadherin / Vimentin		30787271
	Growth inhibition assay	Cell viability		28339092

In Vivo
In Vivo	A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. ^[6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C₂₆ colon carcinoma xenografts. ^[7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. ^[8]
動物実験	動物モデル	Human hepatocellular carcinoma xenografts HCCLM3
	投与量	10 mg/kg
	投与経路	A weekly i.p. injection

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05922358	Not yet recruiting	Gastrointestinal Tumors	Fujian Cancer Hospital	September 1 2023	Phase 2
NCT05780684	Recruiting	Colorectal Cancer\|Esophagus Cancer\|Appendix Cancer\|Small Bowel Cancer\|Ampullary Cancer	Dartmouth-Hitchcock Medical Center	July 14 2023	Not Applicable
NCT05322590	Recruiting	Metastatic Colorectal Carcinoma\|Neuropathy	Bexion Pharmaceuticals Inc.\|ICON plc\|CTI Clinical Trial and Consulting Services	January 9 2023	Phase 1\|Phase 2
NCT05068531	Recruiting	Colorectal Cancer Metastatic	Centre hospitalier de l''Université de Montréal (CHUM)\|Exactis Innovation\|Chaire Roger Des Groseillers d''oncologie chirurgicale HBP de l''Université de Montréal\|Canexia Health	September 1 2022	--
NCT05031975	Recruiting	Colorectal Cancer	Fondazione IRCCS Istituto Nazionale dei Tumori Milano	May 2 2022	Phase 2
NCT05025826	Recruiting	Metastatic Gastric Cancer	Nantes University Hospital\|Algosource	April 1 2022	Not Applicable

参考
[1] Raymond E et al, Ann Oncol, 1998, 9(10), 1053-1071. [2] Mohammed MQ, et al. Anticancer Drugs, 2000, 11(10), 859-863. [3] Kirstein MN, et al. Anticancer Drugs, 2008, 19(1), 37-44. [4] Pendyala L, et al. Cancer Res, 1993, 53(24), 5970-5976. [5] Espinosa M, et al. Cancer Chemother Pharmacol, 2005, 55(3), 301-305. [6] Wang Z, et al. Expert Opin Investig Drugs, 2009, 18(11), 1595-1604. [7] Math?G, et al. Biomed Pharmacother, 1989, 43(4), 237-250. [8] Schellingerhout D, et al. PLoS One, 2012, 7(9), e45776. [9] Matthew D Hall, et al. Cancer Res. 2014 Jul 15;74(14):3913-22. + 展開

参考

+ 展開

化学情報

分子量	397.29	化学式	C₈H₁₄N₂O₄Pt
CAS No.	61825-94-3	SDF	Download Oxaliplatin SDFをダウンロードする
Smiles	C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
保管	2 years 4°C(in the dark) powder	溶液状態は不安定なので使用直前に調整してください。少量づつ分包して保管し、都度使い切る事が推奨されます。

In vitro
Batch:

Water : 2 mg/mL

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

よくある質問（FAQ）

質問1:
Is it ok to dissolve Oxaliplatin in saline?

回答
Oxaliplatin is partially converted to cisplatin and L-isomers when dissolved in saline. The L-isomer of oxaliplatin is inactive. DMF is a better choice.

質問2:
Is it ok to dissolve Oxaliplatin in DMSO?

回答
Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):